Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway
Diabetes, Metabolic Syndrome and Obesity · 2024-02 · Volume 17 · 575-584
DOI: 10.2147/dmso.s447182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2024-02. Verfasst von Zhanlin Liao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine, Affiliated Nanping First Hospital of Fujian Medical University, Nanping, Fujian, 353006, People's Republic of China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Type 2 diabetes (T2DM) combined nonalcoholic fatty liver disease (NAFLD) are characterized by metabolic disruptions. Liraglutide has been proved to be effective in T2DM. If LRG could regulate NAFLD combined T2DM has not been reported.
Methods
Intraperitoneal injection of 1% streptozotocin (STZ) plus high-sugar and high-fat diet was used to induce NAFLD combined T2DM animal model. Palmitic acid (200 µmol/L) and glucose (25 mmol/L) incubation were used to induce cell model. The cell apoptosis, mRNA and protein expression were measured through flow cytometry, PCR, and Western blotting, respectively.
Results
Liraglutide significantly improved the liver injury of NAFLD combined T2DM rats, but Com-C reversed the effect of liraglutide. The decreased AMPK/mTOR signaling pathway in the NAFLD combined T2DM animals was greatly activated by liraglutide. Com-C reversed the protection effects of liraglutide on palmitic acid+glucose induced cell damage.
Conclusion
Liraglutide could greatly alleviate the damage caused by NAFLD+T2DM and palmitic acid+glucose. The protection effects of liraglutide were greatly inhibited by suppressing AMPK/mTOR signaling pathway. This research might provide a novel therapeutic strategy for the prevention and treatment of NAFLD combined T2DM disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrine, Affiliated Nanping First Hospital of Fujian Medical University, Nanping, Fujian, 353006, People's Republic of China.
- Department of Ophthalmology, Affiliated Nanping First Hospital of Fujian Medical University, Nanping, Fujian, 353006, People's Republic of China.
Zitieren
APA
Liao, Z., Huang, L., Chen, J., Chen, T., Kong, D., Wei, Q., Chen, Q., Deng, B., Li, Y., Zhong, S., & Huang, Z. (2024). Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway. Diabetes, Metabolic Syndrome and Obesity, Volume 17, 575-584. https://doi.org/10.2147/dmso.s447182
Vancouver
Liao Z, Huang L, Chen J, Chen T, Kong D, Wei Q, et al. Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway. Diabetes, Metabolic Syndrome and Obesity. 2024;Volume 17:575-584. doi:10.2147/dmso.s447182
BibTeX
@article{Liao2024,
author = {Liao, Zhanlin and Huang, Liangzhi and Chen, Jun and Chen, Ting and Kong, Dezhi and Wei, Qifeng and Chen, Qiao and Deng, Bin and Li, Yanyan and Zhong, Shuai and Huang, Zugui},
title = {Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2024},
volume = {Volume 17},
pages = {575--584},
doi = {10.2147/dmso.s447182}
}
EUVIMED